Pcna inhibitors
US-2024343682-A1 · Oct 17, 2024 · US
Myc-Max inhibitor compound therapeutics for cancer treatment, methods and uses associated therewith
US12017975B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12017975-B2 |
| Application number | US-202217966227-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 14, 2022 |
| Priority date | Sep 5, 2018 |
| Publication date | Jun 25, 2024 |
| Grant date | Jun 25, 2024 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Provided herein are Myc-Max inhibitory compounds having the structure of Formula (I) and compositions thereof for use in the treatment of cancer. In particular, the Myc-Max inhibitory compounds may be useful for the treatment of cancers selected from one or more of: prostate cancer, breast cancer, colon cancer, cervical cancer, small-cell lung carcinomas, neuroblastomas, osteosarcomas, glioblastomas, melanoma and myeloid leukaemia.
First claim
Opening claim text (preview).
We claim: 1. A method of cancer treatment, the method comprising administering a compound having the structure to a patient in need thereof, wherein the cancer is selected from one or more of the following: prostate cancer; breast cancer; colon cancer; cervical cancer; small-cell lung carcinoma; neuroblastomas; osteosarcoma; glioblastoma; melanoma; and myeloid leukaemia. 2. The method of claim 1 , wherein the cancer is selected from prostate cancer, breast cancer, colon cancer, cervical cancer, and small-cell lung carcinoma. 3. The method of claim 1 , wherein the cancer is prostate cancer. 4. The method of claim 1 , wherein the cancer is breast cancer. 5. The method of claim 1 , wherein the cancer is colon cancer. 6. The method of claim 1 , wherein the cancer is cervical cancer. 7. The method of claim 1 , wherein the cancer is small-cell lung carcinoma. 8. The method of claim 1 , wherein the cancer is a neuroblastoma. 9. The method of claim 1 , wherein the cancer is an osteosarcoma. 10. The method of claim 1 , wherein the cancer is a glioblastoma. 11. The method of claim 1 , wherein the cancer is a melanoma. 12. The method of claim 1 , wherein the cancer is a myeloid leukaemia.
Assignees
Inventors
Classifications
Ortho-condensed systems · CPC title
linked by a chain containing hetero atoms as chain links · CPC title
linked by a carbon chain containing only aliphatic carbon atoms · CPC title
linked by a chain containing hetero atoms as chain links · CPC title
linked by a carbon chain containing only aliphatic carbon atoms · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12017975B2 cover?
- Provided herein are Myc-Max inhibitory compounds having the structure of Formula (I) and compositions thereof for use in the treatment of cancer. In particular, the Myc-Max inhibitory compounds may be useful for the treatment of cancers selected from one or more of: prostate cancer, breast cancer, colon cancer, cervical cancer, small-cell lung carcinomas, neuroblastomas, osteosarcomas, glioblas…
- Who is the assignee on this patent?
- Univ British Columbia
- What technology area does this patent fall under?
- Primary CPC classification C07C237/22. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jun 25 2024 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).